Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 139

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 139
---
 resulting from, arising out of, suffered, or incurred by Kaken relating to:

| • |     | the failure of certain representations by Aadi, or any representation in any certificate delivered by Aadi                                                                                                                                              
 pursuant to the Divestiture Agreement, to be true and correct in all respects, whether as of the date of the Divestiture Agreement or as of the date of completion of the Divestiture (as if made as of the date of the completion of the Divestiture); |

| • |     | Aadi’s breach of or failure to comply with any covenant or other agreement by Aadi contained in the 
 Divestiture Agreement;                                                                              |

| • |     | Aadi Sub’s breach of or failure to comply with any covenant or other agreement by Aadi Sub contained in the                                    
 Divestiture Agreement, to the extent such covenant or agreement was required to be performed prior to or at the completion of the Divestiture; |

| • |     | all amounts that should have been but were not included in Aadi Sub’s transaction expenses and should as a                             
 result be excluded from the aggregate amount of all cash and cash equivalents held by Aadi Sub upon the completion of the Divestiture; |

| • |     | all fees, costs, expenses and other amounts incurred or otherwise borne by Aadi Sub directly or indirectly to 
 consummate the Pre-Closing Restructuring;                                                                     |

| • |     | certain litigation-related costs; |

| • |     | certain policy exclusions under the RWI Policy; and |

| • |     | certain pre-closing tax matters. |

Limitations on Liability Subject to certain exclusions in the case of claims of fraud against Aadi, the exclusive remedies of Kaken and the other indemnified parties under the Divestiture Agreement for losses under the Divestiture Agreement are (1) the recovery of 50% of the amount of such losses from Aadi until the indemnified parties under the Divestiture Agreement have recovered from Aadi with respect to indemnification claims an amount equal to 50% of retention amount, which is equal to $600,000 (the “Retention Amount”), and (2) resorting to the insurance coverage under the RWI Policy. Any indemnification for losses under the Divestiture Agreement will be net of the amount of any insurance proceeds actually received by the applicable indemnified party with respect to such losses, reduced by the amount of any increase in premium or other expense incurred by such indemnified party in connection